American Oriental Bioengineering Reports First Quarter 2009 Financial Results
Bioengineering, Inc. (NYSE: AOB), a pharmaceutical company dedicated to
improving health through the development, manufacture and commercialization of
a broad range of prescription and over the counter (“OTC”) products in
today announced financial results for the first quarter ended
Revenue in the first quarter of 2009 increased 18.9% year over year to
Company’s core pharmaceutical and nutraceutical products. Revenue from
pharmaceutical products increased 8.9% to
the prior year’s first quarter. Prescription pharmaceutical products revenue
increased 14.5% to
prescription formulation Jinji and CCXA products, which offset declines in
Shuanghuanglian Injection Powder (“SHL”). OTC pharmaceutical products
flat to the prior year period, reflecting continued demand for Boke nasal
spray and Jinji Yimucao products and a shift of Jinji Capsule products from
OTC to prescription sales. Nutraceutical products generated revenue of
prior year period, reflecting continued demand for peptide products and an
expanded distribution network versus the prior year’s first quarter. The
Gross profit in the first quarter of 2009 increased 8.1% to
compared with 67.8% in the prior year period, reflecting lower margin
distribution revenue and CCXA’s generic product sales.
Operating income in the first quarter was
operating expenses to
as selling and marketing expenses increased 9.3% to
and promotional initiatives related to Jinji and Boke products. Advertising
expense increased 26.7% to
Net income for the first quarter of 2009 was
expense related to the Company’s outstanding convertible notes in the first
quarter of 2009, which did not occur in the first quarter of 2008, net income
performance was roughly flat on a year over year basis. Net income per
diluted share was
diluted share in the first quarter of 2008.
Bioengineering, commented, “We are pleased with our first quarter performance
and have met our key near-term objective to foster a dynamic business model
that is diversified across prescription, OTC and nutraceutical products.
Notably, our distribution business began to strengthen overall performance
this quarter, contributing to net income as anticipated, and enlarging our
distribution reach, particularly for our prescription pharmaceutical products.
We are more flexible today than we were one year ago and, because of this, we
can quickly adapt to change and capitalize on new opportunities despite the
uncertain regulatory environment. Our marketing capabilities, extensive
distribution platform, compelling product portfolio and ongoing rural
expansion offset anticipated challenges in SHL sales during the first quarter
of 2009 and we remain focused on becoming a top five pharmaceutical company in
The Company will hold a conference call at
discuss first quarter 2009 results. Listeners may access the call by dialing
1-866-798-2884 or 1-617-614-6207 for international callers, access code:
34266051. A webcast will also be available through AOBO’s website at
http://www.bioaobo.com . A replay of the call will be available through
1-617-801-6888 for international callers, access code: 57318398.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a
company dedicated to improving health through the development, manufacture and
commercialization of a broad range of prescription and over the counter
Statements made in this press release are forward-looking and are made
pursuant to the safe harbor provisions of the Securities Litigation Reform Act
of 1995. Such statements involve risks and uncertainties that may cause
actual results to differ materially from those set forth in these statements.
The economic, competitive, governmental, technological and other factors
identified in the Company’s filings with the Securities and Exchange
Commission, including the Form 10-K for the year ended
cause actual results or events to differ materially from those described in
the forward looking statements in this press release. The Company undertakes
no obligation to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED) THREE MONTHS ENDED March 31 2009 2008 REVENUES $46,077,190 $38,768,598 COST OF GOODS SOLD 17,660,338 12,477,636 GROSS PROFIT 28,416,852 26,290,962 Selling and marketing 5,211,502 5,029,708 Advertising 5,567,357 4,394,341 General and administrative 4,565,643 3,912,683 Depreciation and amortization 1,858,915 977,210 Total operating expenses 17,203,417 14,313,942 INCOME FROM OPERATIONS 11,213,435 11,977,020 EQUITY IN EARNINGS (LOSS) FROM UNCONSOLIDATED ENTITIES 437,794 -- INTEREST INCOME (EXPENSE), NET (1,579,269) 16,847 OTHER (EXPENSE), NET (98,609) (101,790) INCOME BEFORE INCOME TAXES 9,973,351 11,892,077 INCOME TAXES 2,103,299 2,469,948 NET INCOME 7,870,052 9,422,129 NET INCOME ATTRIBUTABLE TO NON- CONTROLLING INTEREST (3,551) -- NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST 7,866,501 9,422,129 OTHER COMPREHENSIVE INCOME Foreign currency translation gain, net of tax 378,466 6,934,434 OTHER COMPREHENSIVE INCOME, NET OF TAX 378,466 6,934,434 COMPREHENSIVE INCOME $8,244,967 $16,356,563 NET INCOME PER COMMON SHARE BASIC $0.11 $0.12 DILUTED $0.11 $0.12 WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING BASIC 74,538,593 78,191,242.00 DILUTED 86,917,603 78,192,795.00 AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS March 31, DECEMBER 31, 2009 2008 UNAUDITED CURRENT ASSETS Cash and cash equivalents $73,899,602 $70,636,510 Accounts receivable, net of reserve of $130,631 and $226,330 at March 31, 2009 and December 31, 2008, respectively 31,812,778 36,982,167 Inventories, net of provision for slow moving inventories 17,954,075 13,042,123 Advances to suppliers 2,241,176 3,593,979 Notes receivable 1,039,914 708,076 Refundable deposit 6,397,106 6,396,996 Tax refund claims 823,737 -- Deferred tax assets 456,444 347,216 Other current assets 863,554 744,903 Total Current Assets 135,488,386 132,451,970 LONG-TERM ASSETS Plant and equipment, net 97,192,300 98,154,443 Land use rights, net 148,319,092 148,988,870 Deposit for long-term assets 6,355,148 6,347,174 Construction in progress 25,675,899 25,385,835 Deferred tax assets 1,322,194 1,313,832 Other intangible assets, net 22,426,393 23,690,440 Goodwill 28,543,226 28,543,226 Investments in and advances to equity investments 55,554,438 54,963,064 Unamortized financing costs 3,983,911 4,215,983 Total Long-Term Assets 389,372,601 391,602,867 TOTAL ASSETS $524,860,987 $524,054,837 LIABILITIES AND SHAREHOLDERS' EQUITY DECEMBER 31, DECEMBER 31, 2008 2007 UNAUDITED CURRENT LIABILITIES Accounts payable $10,355,431 $12,287,887 Notes payables 3,277,285 3,262,877 Other payables and accrued expenses 13,578,351 19,766,652 Taxes payable -- 420,671 Short-term bank loans 7,441,276 7,140,148 Current portion of long-term bank loans 59,022 58,659 Other liabilities 2,738,113 2,253,440 Deferred tax liability 999,454 846,026 Total Current Liabilities 38,448,932 46,036,360 LONG-TERM LIABILITIES Long-term bank loans 789,579 804,521 Long-term notes payable -- 269,908 Deferred tax liabilities 16,102,048 16,083,768 Convertible Note 115,000,000 115,000,000 Total Long-Term Liabilities 131,891,627 132,158,197 TOTAL LIABILITIES 170,340,559 178,194,557 EQUITY SHAREHOLDERS' EQUITY Preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,000,000 shares issued and outstanding at March 31, 2009 and December 31, 2008, respectively 1,000 1,000 Common stock, $0.001 par value; 150,000,000 shares authorized; 78,291,735 and 78,249,264 shares issued and outstanding at March 31, 2009 and December 31, 2008, respectively 78,292 78,249 Common stock to be issued 177,000 376,335 Prepaid forward repurchase contract (29,998,616) (29,998,616) Additional paid-in capital 196,352,466 195,741,544 Retained earnings (the restricted portion of retained earnings is $29,532,699 at March 31, 2009 and December 31, 2008) 157,790,182 149,923,681 Accumulated other comprehensive income 29,464,472 29,086,006 Total Shareholders' Equity 353,864,796 345,208,199 NONCONTROLLING INTEREST 655,632 652,081 TOTAL EQUITY 354,520,428 345,860,280 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $524,860,987 $524,054,837
SOURCE American Oriental Bioengineering, Inc.